UMOD has been replicated in GWAS (Evangelou et al., 2018) and is a target currently being tested in a clinical trial for its interaction with NKCC2 in hypertension – as UMOD genotypes of increased or decreased expression affect salt sensitivity in the kidney and a person’s propensity for hypertension. The gene discussed is SLC12A1; the disease is Hypertension.